SCHEMBL16480436

SCHEMBL16480436

CCC1CCCN1CC1CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 3/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
ACHE P22303 1/20 0.32
CHRM5 P08912 1/20 0.32
ADRA2C P18825 1/20 0.32
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
S1PR1 P21453 2/20 0.32
S1PR3 Q99500 2/20 0.32
S1PR5 Q9H228 2/20 0.32
S1PR4 O95977 1/20 0.32
CNR1 P21554 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12717512 1.00 MAPK1 (0.36) MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2
SCHEMBL172614 0.92 CHRM5 (0.43) MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2
SCHEMBL9893069 0.92 CHRM5 (0.43) MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2
SCHEMBL14665103 0.88 CHRM5 (0.48) MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2
SCHEMBL9893057 0.87 HSD11B1 (0.41) MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2
SCHEMBL12718154 0.83 S1PR1 (0.40) ALDH1A1L3MBTL1ACHES1PR1S1PR3
SCHEMBL12718159 0.83 S1PR1 (0.40) ALDH1A1L3MBTL1ACHES1PR1S1PR3
SCHEMBL27126557 0.81 GBA1 (0.40) MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2
SCHEMBL9893161 0.80 HSD11B1 (0.34) MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2
SCHEMBL23828670 0.79 S1PR1 (0.41) MAPK1ALDH1A1CRHBPCRHR2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023125989-A1 QUINAZOLINE COMPOUND AND APPLICATION THEREOF 上海医药集团股份有限公司 2023-07-06 WO disclosed
WO-2022256554-A1 FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME UNIVERSITY OF THE SCIENCES (US) 2022-12-08 WO disclosed
US-20220298140-A1 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) 2022-09-22 US disclosed
US-8629157-B2 Pyrrolidine compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298140-A1 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF JAK2, FLT3, JAK1 MAPK1 327/4885ALDH1A1 1128/4885CRHBP 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.